Intrathecal rituximab treatment for pediatric post‐transplant lymphoproliferative disorder of the central nervous system
Authors:
- 1 August 2007
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (4) , 886-888
Abstract
Post‐transplant lymphoproliferative disorder (PTLD) in the central nervous system (CNS) has a poor prognosis. New therapeutic approaches should be explored. We report our experience with intrathecal administration of rituximab in a 10‐year‐old kidney allograft recipient with PTLD in the CNS. After standard treatment had failed, we tried to treat the patient by administering rituximab directly into the cerebral ventricle through an Omaya reservoir, in addition to conventional intrathecal and systemic chemotherapy. This strategy resulted in a disappearance of clinical symptoms and a negative positron emission tomogram. Intrathecal administration of rituximab may be a feasible approach in children with PTLD in the CNS. However, its specific role in our patient remains uncertain. Pediatr Blood Cancer 2008;50:886–888.Keywords
This publication has 16 references indexed in Scilit:
- Infectious complications after kidney transplantation: current epidemiology and associated risk factorsClinical Transplantation, 2006
- Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 studyBlood, 2006
- Management of patients with post-transplant lymphoproliferative disorder: the role of rituximabTransplant International, 2006
- Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantationCritical Reviews in Oncology/Hematology, 2005
- Imaging of central nervous system lymphomas with iodine‐123 labeled rituximabEuropean Journal of Haematology, 2005
- Posttransplant Lymphoproliferative Disorder: Significance of Central Nervous System InvolvementTransplantation Proceedings, 2005
- Post-Transplant Lymphoproliferative Disorder in ChildrenPediatric Drugs, 2005
- Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartmentBlood, 2003
- Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell LymphomaLeukemia & Lymphoma, 2001
- TREATMENT OF CENTRAL NERVOUS SYSTEM B LYMPHOPROLIFERATIVE SYNDROME BY LOCAL INFUSION OF A B CELL-SPECIFIC MONOCLONAL ANTIBODYTransplantation, 1992